



United States of America
FEDERAL TRADE COMMISSION
WASHINGTON, DC 20580

January 24, 2013

Sharis A. Pozen, Esq.
Counsel For Illumina, Inc.
Skadden, Arps, Slate, Meagher & Flom LLP
1440 New York Avenue, N.W.
Washington, DC 20005

Re: *Proposed Acquisition of Complete Genomics, Inc. by Illumina, Inc.,
File No. 131-0033*

Dear Ms. Pozen:

The Federal Trade Commission's Bureau of Competition has been conducting a nonpublic investigation to determine whether the proposed acquisition of Complete Genomics, Inc. by Illumina, Inc. may violate Section 7 of the Clayton Act or Section 5 of the Federal Trade Commission Act.

By a letter dated January 8, 2013, counsel for Illumina, Inc. notified the Bureau of Competition that it was withdrawing its tender offer and the accompanying Hart-Scott-Rodino filing. Based upon this representation, it now appears that no further action is warranted by the Commission at this time. Accordingly, the investigation has been closed. This action is not to be construed as a determination that a violation may not have occurred, just as the pendency of an investigation should not be construed as a determination that a violation has occurred. The Commission reserves the right to take such further action as the public interest may require.

By direction of the Commission.

Donald S. Clark
Secretary